What is (+/-)-Mianserin used for?

(+/-)-Mianserin is indicated for Major depressive disorder.

What development phase is (+/-)-Mianserin in?

(+/-)-Mianserin is FDA-approved (marketed).

What is the generic name of (+/-)-Mianserin?

MIANSERIN is the generic (nonproprietary) name of (+/-)-Mianserin.

Last reviewed 2026-04-20 · How we verify

(+/-)-Mianserin (MIANSERIN)

FDA-approved withdrawn Small molecule Quality 26/100

At a glance

Generic name	MIANSERIN
Drug class	mianserin
Target	Histamine H1 receptor
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

Major depressive disorder

Common side effects

No common side effects on file.

Key clinical trials

A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems (PHASE4)
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
Treatment of Sleep Disturbances in Trauma-affected Refugees (PHASE4)
Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(+/-)-Mianserin CI brief — competitive landscape report
(+/-)-Mianserin updates RSS · CI watch RSS